Georgia Department of Community Health (GDCH)
&
Express-Scripts, Inc. (ESI)

Opportunities for Pharmaceutical Manufacturer Input on Clinical Recommendations and Clinical Management Strategies by the Drug Utilization Review Board

Clinical Information and Clinical Management Strategies relevant to the quality of care and management of the GDCH Medicaid, PeachCare for Kids, State Health Benefit, and Board of Regents Health Plans will be presented to the Drug Utilization Review Board at each meeting by ESI's Clinical Program Managers. Manufacturer input on information and recommendations is welcomed and appreciated through the following methods.

Opportunity for Presentation:

Manufacturers' Forum: The forum is held prior to each DURB meeting whereby manufacturers may present:

1) Clinical information relevant to drugs that will be reviewed at the next DURB meeting.

2) Clinical information relevant to ongoing ESI Clinical Management Strategy development (e.g. review of drug benefit-plan designs, new drugs coming to market, new drug indications, etc.)

Opportunity for Recommendations:

DUR Board Meeting Process: Clinical Information for discussion by the Board will be posted to the GDCH web site approximately 30 days prior to DURB meetings. Manufacturer comments and input specific to the drugs under review are made in writing directly to ESI and reported as determined to be appropriate by ESI at the upcoming DURB meeting.

Upon review of Clinical Information presented by ESI, the DURB makes recommendations to GDCH

Opportunity for Meeting with GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH's internal clinical committee after each DURB meeting. Manufacturers that would like to discuss new information that was not provided at the most recent forum or meeting may make an appointment to present it within the 10 business days following each DURB meeting. Contact: Rose Duncan at 404-657-7247.